List of Excipients in Branded Drug ALEVE LIQUID GELS

« Back to Dashboard

Generic Drugs Containing ALEVE LIQUID GELS

Company	Ingredient	NDC	Excipient
Bayer Healthcare LLC	naproxen sodium	0280-0105	AMMONIA
Bayer Healthcare LLC	naproxen sodium	0280-0105	FD&C BLUE NO. 1
Bayer Healthcare LLC	naproxen sodium	0280-0105	GELATIN

What are the Most Frequently-Used Excipients in ALEVE LIQUID GELS?

# Of NDCs	Excipient
1	AMMONIA
1	FD&C BLUE NO. 1
1	GELATIN

Aleve Liquid Gels Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Aleve Liquid Gels is an established naproxen sodium softgel product with limited opportunity for new-ingredient differentiation but meaningful potential in formulation engineering, manufacturability, sustainability, dosing convenience, and line extensions. The core active-ingredient protection is long expired. Commercial value therefore depends on brand equity, regulatory compliance, capsule performance, consumer experience, supply economics, and defensible delivery-system improvements.

What is the formulation of Aleve Liquid Gels?

Aleve Liquid Gels contains naproxen sodium equivalent to 220 mg of naproxen per capsule. It is an immediate-release oral softgel intended for temporary relief of minor aches and pains and reduction of fever in adults and children aged 12 years and older.[1]

Public U.S. labeling identifies the formulation as a liquid-filled gelatin capsule. Listed inactive ingredients include components associated with the capsule shell, liquid vehicle, color, printing ink, and processing system. The exact excipient declaration can vary by product presentation, manufacturing site, and market.

Formulation element	Likely function in Aleve Liquid Gels
Naproxen sodium	Active pharmaceutical ingredient
Gelatin	Softgel shell-forming polymer
Glycerin	Plasticizer and shell humectant
Sorbitol	Plasticizer, humectant, and shell-property modifier
Purified water	Shell and fill processing medium
Povidone	Solubilizing, binding, or viscosity-control function
Propylene glycol	Solvent and cosolvent
Mineral oil or related lipid vehicle	Fill-phase carrier, where used in the applicable presentation
Lecithin or surfactant system	Wetting and dispersion support, where used
Colorants	Product identification and consumer recognition
Pharmaceutical ink	Capsule imprinting

The capsule is a formulation system rather than a simple liquid dosage form. Its commercial performance depends on the interaction between the fill vehicle, gelatin shell, plasticizer ratio, water migration, oxygen exposure, sealing conditions, and storage environment.

Why is naproxen sodium used instead of naproxen?

Naproxen sodium is the sodium salt of naproxen. It has greater aqueous solubility than the free acid, which supports dissolution and absorption from an oral immediate-release dosage form. The salt does not eliminate the need for formulation control. Precipitation, pH effects, fill viscosity, shell compatibility, and long-term stability remain relevant development issues.

The active ingredient is an established nonsteroidal anti-inflammatory drug. Its novelty value is therefore low. Excipient selection must support product performance and consumer differentiation rather than attempt to create a new active-ingredient position.

What excipient functions create the strongest commercial opportunities?

The largest opportunities are in excipients that improve capsule robustness, reduce manufacturing loss, increase chemical stability, or create a legally defensible product difference.

Softgel shell optimization

Gelatin remains the dominant commercial shell material for conventional softgels because it supports rapid processing, reliable sealing, and broad manufacturing availability. Its limitations include animal origin, moisture sensitivity, brittleness at low humidity, and cross-linking risk under certain chemical conditions.

Potential development paths include:

• Gelatin systems with optimized glycerin and sorbitol ratios.
• Modified gelatin systems that reduce brittleness and improve seal integrity.
• Non-gelatin shells based on starch, modified cellulose, carrageenan, or other hydrocolloid combinations.
• Lower-moisture shells for improved stability of moisture-sensitive fills.
• Shell systems with improved resistance to oxygen and light transmission.
• Vegetarian or halal-compatible alternatives.

A replacement shell must match the existing product in dissolution, rupture, leakage resistance, appearance, consumer handling, and shelf life. A plant-based shell could support premium positioning, but it would face higher technical and manufacturing risk than a gelatin optimization.

Fill-phase solubilization and dispersion

Naproxen sodium is more soluble than naproxen, but a liquid-filled capsule still requires a stable fill system. Relevant excipient strategies include:

• Polyethylene glycol or propylene glycol-based solvent systems.
• Polyol blends that control viscosity and crystallization.
• Surfactants that improve wetting and maintain a uniform fill.
• Lipid or self-emulsifying systems for improved dispersion.
• pH-modified vehicles that reduce precipitation during storage.
• Antioxidant systems where justified by degradation pathways.
• Chelating agents where trace metals contribute to instability.

A formulation that remains homogeneous during storage can reduce dose variability, fill-line interruptions, and reject rates. The development target is not simply higher solubility. It is a commercially manufacturable fill with acceptable shell compatibility and rapid release.

Moisture and oxygen control

Softgels exchange moisture with the environment. Water can migrate between the fill and shell, changing capsule hardness, elasticity, dissolution, and leakage risk. Oxygen and light can also affect the active ingredient or excipient system.

Commercial improvements may include:

• Higher-barrier blister packaging.
• Desiccant-supported bottle systems.
• Oxygen-reduced headspace.
• Light-protective packaging.
• Shell formulations with lower permeability.
• Fill systems with reduced water activity.
• Packaging validated for hot and humid markets.

Packaging changes can be commercially attractive because they may require less reformulation than a new shell or fill. They can also support geographic expansion where climate-zone stability is a constraint.

What formulations are protected by Aleve Liquid Gels patents?

The historical naproxen and naproxen sodium patent estate is expired or commercially weak in the United States. The principal opportunity is not protection of naproxen sodium itself but protection of specific formulation architecture.

Potentially protectable subject matter includes:

1. A defined liquid vehicle that maintains naproxen sodium in solution or stable dispersion.
2. A shell composition with specified gelatin, plasticizer, moisture, and viscosity ranges.
3. A capsule with improved dissolution after storage.
4. A fill-shell combination that limits migration or leakage.
5. A packaging system that preserves stability under elevated temperature and humidity.
6. A softgel manufacturing process that improves content uniformity or reduces defects.
7. A combination product containing naproxen sodium and another active ingredient.
8. A new dosage regimen or patient population, where the regulatory and patent standards are met.

A patent directed only to a broad list of conventional excipients would face substantial validity and enforceability risk. Stronger claims would require a defined composition, measurable performance advantage, and evidence that the result was not predictable from the prior art.

How strong is the patent estate for Aleve Liquid Gels?

The estate is best characterized as weak for the active ingredient and potentially moderate for narrowly drafted formulation, process, packaging, or combination-product claims.

Asset category	Commercial protection outlook
Naproxen sodium active ingredient	Expired or nonexclusive
Basic immediate-release tablet or capsule	Low
Conventional gelatin softgel	Low to moderate
Specific fill vehicle	Moderate if technically differentiated
Shell-fill compatibility system	Moderate to strong if supported by data
Manufacturing process	Moderate, subject to detectability
Packaging and stability system	Moderate
Combination product	Potentially stronger, depending on actives and claims
New method of use	Potentially available but requires supporting evidence
Brand and trade dress	Commercially important, outside patent protection

The strongest defensible position would combine patent rights with trade secrets covering fill composition, process parameters, equipment settings, supplier specifications, and stability-control methods.

When does Aleve Liquid Gels lose exclusivity?

Aleve Liquid Gels does not rely on a current U.S. new-drug patent monopoly in the way a recently approved prescription product does. Naproxen sodium is an old active ingredient, and the product is marketed under the FDA nonprescription framework.

The relevant exclusivity dates are therefore:

Exclusivity type	Status
New chemical entity exclusivity	Not applicable
Prescription drug patent exclusivity	Not the primary commercial barrier
OTC monograph access	Available for compliant products
Brand protection	Continues while the mark is maintained and used
Trade dress protection	Continues if the design remains distinctive
Formulation patent protection	Depends on individual patent claims and expiration
Regulatory exclusivity for a novel OTC product	Potentially available only for qualifying innovation

A competing manufacturer generally does not need to wait for an Aleve-specific patent expiration to market an OTC naproxen sodium product if it satisfies the applicable FDA requirements and avoids protected trademarks, trade dress, and enforceable formulation claims.

What is the Orange Book status of Aleve Liquid Gels?

Aleve Liquid Gels is not best analyzed through the Orange Book. The Orange Book primarily identifies approved prescription drug products, therapeutic equivalence evaluations, patents, and regulatory exclusivities associated with approved applications.[2]

OTC naproxen sodium products are generally evaluated under the FDA monograph framework and applicable labeling, manufacturing, testing, and registration requirements. The absence of an Orange Book listing does not mean the product has no intellectual-property protection. Trademark rights, formulation patents, process patents, packaging claims, and confidential manufacturing know-how may still affect competition.

Are there Paragraph IV challenges to Aleve Liquid Gels?

A conventional Paragraph IV strategy is unlikely to be the main route for challenging a monograph-based OTC naproxen sodium softgel. Paragraph IV certifications apply to patents listed in the Orange Book for an approved drug application. A competing OTC manufacturer would more commonly pursue a compliant monograph product or another FDA pathway rather than challenge Aleve through a prescription-style abbreviated new drug application.

The practical competitive questions are:

• Whether the proposed product complies with the applicable OTC naproxen requirements.
• Whether its labeling matches FDA requirements.
• Whether its dosage form and excipient system are permitted.
• Whether it infringes a live formulation or process patent.
• Whether its appearance creates trade-dress exposure.
• Whether its manufacturing site can meet current good manufacturing practice standards.

What FDA regulatory requirements affect excipient commercialization?

Excipient changes can trigger different regulatory consequences depending on whether the product remains within the applicable OTC monograph conditions.

A manufacturer should evaluate:

• The identity and concentration of each inactive ingredient.
• FDA Inactive Ingredient Database precedent.
• Oral safety history and permitted use levels.
• Color additive authorization.
• Gelatin source and animal-origin controls.
• Allergen and dietary-positioning implications.
• Dissolution and disintegration performance.
• Assay, impurities, degradation products, and content uniformity.
• Stability under applicable ICH conditions.
• Capsule leakage, brittleness, deformation, and seal integrity.
• Labeling changes and Drug Facts compliance.
• Current good manufacturing practice controls under 21 C.F.R. Parts 210 and 211.

A novel excipient or an unusual concentration may require a regulatory strategy outside the simplest monograph route. The commercial value of an excipient innovation declines sharply if it creates a regulatory review burden disproportionate to the consumer benefit.

What generic entry risks exist for Aleve Liquid Gels?

Generic and private-label entry risk is high because the active ingredient is old, widely available, and suitable for multiple dosage forms. The main barriers are commercial rather than molecule-specific.

Entry scenarios

Scenario	Likely timing	Competitive effect
Standard naproxen sodium tablets	Short	Price pressure on the broader category
Conventional naproxen sodium softgels	Short to medium	Direct dosage-form substitution
Store-brand liquid gels	Short to medium	Retailer margin expansion and brand-price compression
Vegetarian or clean-label softgels	Medium	Premium niche competition
Faster-release or easier-swallowing capsules	Medium	Consumer segmentation
Combination analgesic products	Medium	Basket and indication competition
Lower-cost imported products	Variable	Supply and pricing pressure

The most vulnerable part of the brand is the undifferentiated 220 mg analgesic segment. The most defensible part is the combination of recognition, retail placement, packaging, consumer trust, and consistent capsule performance.

Which companies are challenging the Aleve Liquid Gels position?

Competition comes from several groups rather than a single patent challenger:

• Private-label retailers selling naproxen sodium tablets and softgels.
• Generic pharmaceutical manufacturers.
• OTC brand owners with competing analgesics.
• Contract manufacturers supplying retailer-owned products.
• Digital-first brands emphasizing clean-label or plant-based formulations.
• Ibuprofen and acetaminophen brands competing for the same pain-relief occasion.
• Combination-product manufacturers targeting nighttime, cold-and-flu, or menstrual-pain segments.

Advil, Motrin, Tylenol, store-brand naproxen products, and combination analgesics compete for overlapping consumer demand. Their patent estates are not directly interchangeable, but their commercial effect is relevant because consumers can switch active ingredients.

How does Aleve Liquid Gels compare with competing analgesic products?

Product category	Active ingredient	Main excipient opportunity	Primary competitive advantage
Aleve Liquid Gels	Naproxen sodium	Softgel fill, shell, stability, swallowability	Long duration of action and established brand
Ibuprofen liquid gels	Ibuprofen	Solubilization, shell compatibility, rapid release	Broad consumer familiarity and rapid-relief positioning
Acetaminophen gelcaps	Acetaminophen	Fill uniformity, shell, taste and swallowability	Different safety and indication profile
Naproxen sodium tablets	Naproxen sodium	Disintegration, coating, compression	Lower manufacturing cost
Combination analgesics	Multiple actives	Compatibility and release separation	Broader symptom targeting

A liquid gel can command a price premium over a tablet only if consumers perceive a benefit in swallowing, onset, convenience, or reliability. The capsule itself is not sufficient differentiation.

What licensing deals could create commercial value?

Licensing opportunities are more likely to involve enabling technology than the naproxen sodium molecule.

Relevant targets include:

• Non-gelatin softgel shell platforms.
• High-barrier capsule and blister technologies.
• Self-emulsifying or supersaturating fill systems.
• Low-moisture softgel manufacturing.
• Continuous encapsulation and defect-detection systems.
• Sustainable plasticizer or shell materials.
• Tamper-evident and child-resistant packaging.
• Combination-product platforms.
• Excipient supplier agreements with dual-source qualification.

A license is commercially attractive if it offers a measurable improvement in shelf life, manufacturing yield, material cost, consumer preference, or regulatory positioning. Broad platform licenses with no demonstrated advantage would have limited value in a mature OTC category.

What manufacturing and IP barriers affect Aleve Liquid Gels?

Manufacturing know-how may provide more practical protection than a narrow formulation patent. Key barriers include:

• Reliable gelatin preparation and viscosity control.
• Accurate fill dosing at high line speeds.
• Uniform capsule sealing.
• Prevention of shell-fill interaction.
• Control of water migration.
• Reduction of leakage and cosmetic defects.
• Stable color and imprint quality.
• Consistent dissolution across production lots.
• Supplier qualification for gelatin, plasticizers, and solvents.
• Validation of cleaning and cross-contamination controls.

Process patents can be difficult to enforce when infringement occurs inside a competitor’s manufacturing plant. Trade-secret protection is stronger where the process parameters are difficult to reverse engineer and employees, suppliers, and contract manufacturers are controlled through confidentiality and access restrictions.

What commercial opportunities are available in Aleve Liquid Gels excipients?

The most credible opportunities rank as follows:

1. Improved softgel shell with lower brittleness and leakage.
2. Vegetarian, halal-compatible, or otherwise differentiated capsule shell.
3. Fill vehicle that improves stability without slowing release.
4. Packaging that extends shelf life in hot and humid conditions.
5. Reduced-cost excipient system that preserves quality and throughput.
6. Easier-to-swallow capsule geometry.
7. Low-waste or lower-carbon manufacturing.
8. Combination products with separate release or indication advantages.
9. Premium products with consumer-relevant excipient claims.
10. Private-label formulations that use the same technical platform at lower cost.

The strongest near-term commercial case is an incremental reformulation that improves manufacturing economics or consumer handling while preserving immediate release and monograph compliance. A radical new excipient platform would face higher regulatory, scale-up, and supply-chain risk.

Key Takeaways

• Aleve Liquid Gels contains naproxen sodium 220 mg per capsule and uses a liquid-filled softgel delivery system.
• The active ingredient has little remaining exclusivity value in the United States.
• Aleve is primarily protected by brand, retail distribution, formulation know-how, packaging, and potential narrow formulation or process rights.
• The product is better analyzed under the OTC monograph framework than through Orange Book exclusivity.
• Paragraph IV litigation is unlikely to be the principal competitive mechanism for a compliant OTC naproxen sodium product.
• The most valuable excipient opportunities involve shell robustness, fill stability, moisture control, sustainability, and manufacturing yield.
• Generic and private-label entry risk is high, but direct competition still requires reliable softgel manufacturing and compliant labeling.
• Revenue exposure for the specific Aleve Liquid Gels SKU is not publicly reported as a standalone figure. Its commercial value is tied to the broader Aleve brand and OTC analgesic portfolio.

FAQs

Can a new excipient create exclusivity for a naproxen sodium softgel?

A new excipient may support patent claims or regulatory differentiation, but it does not automatically create market exclusivity. The formulation must show novelty, non-obviousness, utility, and a defensible claim scope.

Is a vegetarian Aleve-style liquid gel commercially viable?

Yes, if the shell provides acceptable sealing, dissolution, stability, appearance, and manufacturing throughput. The opportunity is strongest in premium, dietary-preference, and international segments.

Can a competitor copy the Aleve Liquid Gels capsule shape?

A competitor may copy functional capsule characteristics but risks trade-dress or design-related claims if its overall appearance is confusingly similar to the branded product.

Which excipients are most likely to reduce softgel manufacturing cost?

The highest-impact candidates are lower-cost plasticizer systems, optimized fill solvents, reduced-defect shell compositions, and packaging materials that reduce stability-related rejects. Cost changes must preserve dissolution and shelf life.

Does naproxen sodium require a novel excipient to be sold in a liquid capsule?

No. An OTC manufacturer can use established excipients that are permitted for the dosage form, supported by safety precedent, and compatible with FDA requirements. Novel excipients may be used for differentiation but create greater regulatory and technical risk.

References

1. U.S. National Library of Medicine. (n.d.). Aleve liquid gels: Drug facts and inactive ingredients. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Over-the-counter monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products.
4. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
5. U.S. Food and Drug Administration. (2024). Current good manufacturing practice, quality system regulation, and pharmaceutical manufacturing requirements.